These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevention of progression of Parkinson's disease with antioxidative therapy. Grimes JD; Hassan MN; Thakar JH Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):165-72. PubMed ID: 3133719 [TBL] [Abstract][Full Text] [Related]
3. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430 [TBL] [Abstract][Full Text] [Related]
4. Type B monoamine oxidase and neurotoxins. Naoi M; Maruyama W Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotective strategies in Parkinson's disease : an update on progress. Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156 [TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M; Srinivasan SK; Baxi MD Prog Neurobiol; 1996 Jan; 48(1):1-19. PubMed ID: 8830346 [TBL] [Abstract][Full Text] [Related]
7. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity]. Herrero MT; Luquín MR; Obeso JA Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423 [TBL] [Abstract][Full Text] [Related]
8. Isoquinoline neurotoxins in the brain and Parkinson's disease. Nagatsu T Neurosci Res; 1997 Oct; 29(2):99-111. PubMed ID: 9359458 [TBL] [Abstract][Full Text] [Related]
9. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. Wei Q; Yeung M; Jurma OP; Andersen JK J Neurosci Res; 1996 Dec; 46(6):666-73. PubMed ID: 8978500 [TBL] [Abstract][Full Text] [Related]
10. MPTP toxicity: implications for research in Parkinson's disease. Kopin IJ; Markey SP Annu Rev Neurosci; 1988; 11():81-96. PubMed ID: 3129982 [TBL] [Abstract][Full Text] [Related]
12. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
13. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sayre LM Toxicol Lett; 1989 Aug; 48(2):121-49. PubMed ID: 2672418 [TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity and neuroprotection in Parkinson's disease. Lange KW; Youdim MB; Riederer P J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247 [TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151 [TBL] [Abstract][Full Text] [Related]
16. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP. Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149 [TBL] [Abstract][Full Text] [Related]
17. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386 [TBL] [Abstract][Full Text] [Related]
18. Oxidative stress: a role in the pathogenesis of Parkinson's disease. Götz ME; Freyberger A; Riederer P J Neural Transm Suppl; 1990; 29():241-9. PubMed ID: 2193108 [TBL] [Abstract][Full Text] [Related]